American Biogenetic Sciences Inc. (MABA) Financials Nov 10, 2014, 12:00 a.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for American Biogenetic Sciences Inc.
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 0 0 0 0 0
Cost of Goods Sold (COGS) incl. D&A 0 0 0 0 0
COGS excluding D&A 0 0 0 0 0
Depreciation & Amortization Expense 0 0 0 - 0
Depreciation 0 - 0 - -
Amortization of Intangibles 0 - 0 - -
Gross Income 0 0 0 0 0
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 40,657 - 67,896 60,500 60,750
Research & Development 0 - 0 - -
Other SG&A 40,657 - 67,896 60,500 60,750
Other Operating Expense 0 - 0 0 0
Unusual Expense 0 0 0 - 0
EBIT after Unusual Expense 0 0 0 - 0
Non Operating Income/Expense 0 - 0 0 0
Non-Operating Interest Income - - - 0 0
Equity in Affiliates (Pretax) 0 - 0 0 -
Interest Expense 2,280 9,120 9,120 9,120 9,120
Gross Interest Expense 2,280 9,120 9,120 9,120 9,120
Interest Capitalized 0 - 0 0 0
Pretax Income (42,937) (62,792) (77,016) (69,620) (69,870)
Income Tax 0 0 0 0 0
Income Tax - Current Domestic 0 - 0 - -
Income Tax - Current Foreign 0 - 0 - -
Income Tax - Deferred Domestic 0 - 0 - -
Income Tax - Deferred Foreign 0 - 0 - -
Income Tax Credits 0 - 0 - -
Equity in Affiliates 0 - 0 0 -
Other After Tax Income (Expense) 0 - 0 0 0
Consolidated Net Income (42,937) (62,792) (77,016) (69,620) (69,870)
Minority Interest Expense 0 0 0 0 0
Net Income (42,937) (62,792) (77,016) (69,620) (69,870)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 - 0 0 0
Cumulative Effect - Accounting Chg 0 - 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (42,937) (62,792) (77,016) (69,620) (69,870)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (42,937) (62,792) (77,016) (69,620) (69,870)
EPS (Basic) () (0.06) - (0.06) (0.06)
Basic Shares Outstanding - 1.09M - 1.09M 1.09M
EPS (Diluted) () (0.06) - (0.06) (0.06)
Diluted Shares Outstanding - 1.09M - 1.09M 1.09M
EBITDA (40,657) (53,672) (67,896) - (60,750)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for American Biogenetic Sciences Inc.
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 0 0 0 0 0
Cost of Goods Sold (COGS) incl. D&A 0 0 0 0 0
COGS excluding D&A 0 0 0 0 0
Depreciation & Amortization Expense 0 0 0 - 0
Depreciation 0 - 0 - -
Amortization of Intangibles 0 - 0 - -
Gross Income 0 0 0 0 0
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 40,657 - 67,896 60,500 60,750
Research & Development 0 - 0 - -
Other SG&A 40,657 - 67,896 60,500 60,750
Other Operating Expense 0 - 0 0 0
Unusual Expense 0 0 0 - 0
EBIT after Unusual Expense 0 0 0 - 0
Non Operating Income/Expense 0 - 0 0 0
Non-Operating Interest Income - - - 0 0
Equity in Affiliates (Pretax) 0 - 0 0 -
Interest Expense 2,280 9,120 9,120 9,120 9,120
Gross Interest Expense 2,280 9,120 9,120 9,120 9,120
Interest Capitalized 0 - 0 0 0
Pretax Income (42,937) (62,792) (77,016) (69,620) (69,870)
Income Tax 0 0 0 0 0
Income Tax - Current Domestic 0 - 0 - -
Income Tax - Current Foreign 0 - 0 - -
Income Tax - Deferred Domestic 0 - 0 - -
Income Tax - Deferred Foreign 0 - 0 - -
Income Tax Credits 0 - 0 - -
Equity in Affiliates 0 - 0 0 -
Other After Tax Income (Expense) 0 - 0 0 0
Consolidated Net Income (42,937) (62,792) (77,016) (69,620) (69,870)
Minority Interest Expense 0 0 0 0 0
Net Income (42,937) (62,792) (77,016) (69,620) (69,870)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 - 0 0 0
Cumulative Effect - Accounting Chg 0 - 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (42,937) (62,792) (77,016) (69,620) (69,870)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (42,937) (62,792) (77,016) (69,620) (69,870)
EPS (Basic) () (0.06) - (0.06) (0.06)
Basic Shares Outstanding - 1.09M - 1.09M 1.09M
EPS (Diluted) () (0.06) - (0.06) (0.06)
Diluted Shares Outstanding - 1.09M - 1.09M 1.09M
EBITDA (40,657) (53,672) (67,896) - (60,750)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
